Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BCT197 add-on treatment for hospitalized acute COPD exacerbation
2015-004631-13Phase 2Completed
- Sponsor
- Mereo BioPharma
- Start
- Feb 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of acumapimod in chronic obstructive pulmonary disease (COPD) (3 arms), sponsored by Mereo BioPharma. Primary endpoint: Change in FEV1 from baseline to Day 7. Started Feb 2016; status: completed.
02
Drugs
acumapimod
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on 2015-004631-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-004631-13.